Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 8.16 Cr.
- Current Price ₹ 2.04
- High / Low ₹ 3.95 / 1.90
- Stock P/E
- Book Value ₹ 1.15
- Dividend Yield 0.00 %
- ROCE -2.77 %
- ROE -15.6 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.02% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 3.85% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 398 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 82.8 days to 154 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 3.46 | 6.44 | 2.66 | 9.56 | 9.89 | 10.39 | 17.81 | 27.84 | 7.39 | 66.28 | |
| 0.06 | 3.77 | 5.84 | 2.68 | 9.90 | 9.80 | 10.45 | 17.14 | 26.76 | 7.75 | 66.35 | |
| Operating Profit | -0.06 | -0.31 | 0.60 | -0.02 | -0.34 | 0.09 | -0.06 | 0.67 | 1.08 | -0.36 | -0.07 |
| OPM % | -8.96% | 9.32% | -0.75% | -3.56% | 0.91% | -0.58% | 3.76% | 3.88% | -4.87% | -0.11% | |
| 0.00 | 0.04 | 0.00 | 0.00 | 0.57 | 0.51 | 0.83 | 0.48 | 0.05 | 0.06 | 0.09 | |
| Interest | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.35 | 0.30 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Profit before tax | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.12 | 0.33 | 0.72 | 0.70 | -0.66 | -0.28 |
| Tax % | 0.00% | 0.00% | 13.04% | 0.00% | 0.00% | 41.67% | 0.00% | 16.67% | 21.43% | 1.52% | |
| -0.06 | -0.31 | 0.21 | -0.44 | -0.21 | 0.08 | 0.33 | 0.60 | 0.55 | -0.67 | -0.31 | |
| EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | -0.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -11% |
| TTM: | 304% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -444% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -23% |
| 3 Years: | -46% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.19 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Reserves | -0.16 | -0.47 | -0.27 | -0.71 | -0.92 | -0.84 | -0.51 | 0.09 | 0.64 | -0.04 | 0.61 |
| 0.50 | 0.90 | 1.32 | 1.48 | 0.39 | 0.36 | 5.51 | 8.00 | 5.17 | 8.65 | 10.14 | |
| 0.11 | 2.73 | 5.10 | 6.33 | 8.89 | 4.93 | 6.56 | 10.39 | 9.69 | 3.85 | 35.00 | |
| Total Liabilities | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.46 | 49.75 |
| 0.00 | 2.31 | 2.31 | 2.31 | 2.31 | 2.32 | 2.32 | 2.31 | 2.34 | 2.33 | 2.33 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.64 | 4.85 | 7.84 | 8.79 | 10.05 | 6.13 | 13.24 | 20.17 | 17.16 | 14.13 | 47.42 | |
| Total Assets | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.46 | 49.75 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | -2.07 | -0.09 | 0.86 | 2.98 | -3.08 | 2.47 | -0.95 | 2.04 | -2.50 | |
| 0.00 | 1.90 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | -0.04 | -0.01 | |
| 0.00 | 0.39 | -0.55 | -0.89 | -2.75 | 2.80 | -2.48 | 1.03 | -1.98 | 2.46 | |
| Net Cash Flow | 0.00 | 0.23 | -0.64 | -0.03 | 0.22 | -0.30 | -0.01 | 0.09 | 0.03 | -0.05 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 266.89 | 287.35 | 782.14 | 249.70 | 230.66 | 275.42 | 255.77 | 151.30 | 398.09 | |
| Inventory Days | 215.20 | 150.49 | 309.32 | 38.07 | 25.93 | 91.82 | 54.64 | 28.27 | 120.95 | |
| Days Payable | 304.36 | 319.46 | 878.47 | 319.47 | 153.98 | 207.06 | 211.26 | 115.76 | 140.22 | |
| Cash Conversion Cycle | 177.72 | 118.38 | 212.99 | -31.71 | 102.61 | 160.18 | 99.15 | 63.81 | 378.83 | |
| Working Capital Days | 332.30 | 237.48 | 469.29 | 109.19 | 104.07 | 102.58 | 50.42 | 44.45 | 153.61 | |
| ROCE % | -10.48% | 12.66% | -0.41% | 5.58% | 16.88% | 12.14% | 10.91% | 10.23% | -2.77% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - With Schedule III Part A Para A of SEBI (LODR) regulations, 2015, we enclose copies of the newspaper advertisments publisherd by the company on 12th …
- Reg. 34 (1) Annual Report. 4 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copies of the postal ballot notice for seeking approval of members of the company, the amendementof the Object Clause of the Memorandum of Association (MOA) …
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
14 Nov - Postal ballot to approve MOA amendment adding plastic/polymer packaging business; e-voting Nov 17–Dec 16, 2025.
-
Results - Financial Results For 30Th September, 2025
14 Nov - Board approved MOA expansion into plastic packaging; postal ballot Nov17–Dec16; CS Chaitra Arora appointed; Q2 Sep30 results approved.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products